The Conversation (0)
Plans to Develop and Launch A Global Registry For The Identification and Long Term Management of Current and Former Boxers With mTBI and PTSD
Insights Derived From This Project Will Help Guide The Development Of Guidelines and Treatment Goals For The WBA Family
Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that the Company plans to develop and launch a global registry for the identification and long term management of current and former boxers with mTBI and PTSD in partnership with the World Boxing Association.
The World Boxing Association (the "WBA"), formerly known as the National Boxing Association ("NBA"), is the oldest of the four major organizations which sanction professional boxing bouts. Led by its longest serving President, Gilberto Jesus Mendoza, the WBA is committed to identifying and implementing more effective management and treatment of mild traumatic brain injury ("mTBI"). President Mendoza stated, "It is no secret that a boxing match is highlighted by skillful defense and aggressive, sometimes violent offensive attacks. From the beginning the WBA has known that a number of our members suffer from the short and long-term effects of varying degrees of mild traumatic brain injury associated with their time competing in the ring. We believe in the promise of the resurgence of psychedelic medicine and are proud to be collaborating with Lobe as we work together to improve the lives and health of members of the WBA family."
Mr. Mendoza continued, "In concert with Lobe Sciences the WBA plans to initiate a first of a kind international registry of current and former WBA boxers who know or suspect that they have suffered from some level of mTBI. Additionally, in conjunction with Lobe and medical experts, we plan to develop a first of its kind protocol to describe the best practices for the early diagnosis and treatment of brain injury to be utilized post fight for current boxers. For the boxers who have retired from active competition, we plan to take a more proactive approach and develop our own symptom tracking and mTBI identification tool to more accurately prioritize appropriate intervention, possibly with the therapeutic regimen being developed by Lobe Sciences."
Philip Young, CEO of Lobe Sciences stated, "This is an ambitious and multifaceted program. Too often patients suffering from mTBI develop post-traumatic stress disorder ("PTSD") and we plan to work to address both the acute trauma and the longer-term condition. Currently, there are no approved pharmaceutical therapies for either mTBI or PTSD. If proven in clinical trials, the combination of NAC (N-Acetylcysteine) and psilocybin may provide a treatment to patients globally. Working with the WBA to explore the identification of and management of both conditions in the WBA community will be an important step in the Company's clinical development for our therapeutic candidates globally."
About Lobe Sciences Ltd.
Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.
For further information please contact:
Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623
NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE NOT REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.
Disclaimer for Forward-Looking Statements
This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company; the development and launch a global registry for the identification and long term management of current and former boxers with mTBI and PTSD; the development of effective delivery methods and commercialization potential of the nasal mist device; research and development using NAC and psilocybin and growth of the business; development of a first of its kind protocol to describe the best practices for the early diagnosis and treatment of brain injury; statements regarding expected timing, advancement and enrollment into future human clinical trials; statements regarding that if proven in clinical trials that combination of NAC (N-Acetylcysteine) and psilocybin may provide a treatment to patients globally; plans to work to address both the acute trauma and the longer-term conditions; statements regarding future approved therapeutics; and the expected timing for the launch of new products and revenue-generating activities, are all forward looking statements that involve risks and uncertainties. Forward-looking statements, by their very nature, require management to make assumptions and are subject to inherent risks and uncertainties, and while management of the Company believes the forward-looking statements contained herein have a reasonable basis, the possibility exists that our predictions, forecasts, projections, expectations or conclusions will not prove to be accurate. Material assumptions that underlie the forward-looking statements included in this news release include, without limitation, assumptions regarding: the outcomes of scientific studies showing the efficacy of psychedelic therapies on mTBI and PTSD, increasing acceptance in the medical community and among consumers for psychedelic therapies as an effective treatment modality; expected synergies from M&A transactions and the timing of future studies, regulatory approvals and our ability to capitalize on business opportunities; and the impact of COVID-19 on our business plans. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. As a result of the inherent uncertainty of forward-looking statements, there can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements, whether as a result of known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. Important risks and uncertainties that could cause actual results to differ materially from the Company's expectations include without limitation risks relating to: that we may not have the capital needed or will not be able to raise sufficient capital to support our business activities or achieve our anticipated milestones; delays or stoppages in the Company's business activities resulting from the COVID-19 pandemic; adverse or unexpected findings in scientific research; adverse changes to the regulatory environment in which we operate; regulatory delays or the failure to obtain required regulatory approvals; failure to capitalize on business opportunities and develop revenue-generating activities; contract counterparty risks; key personnel risk; business integration risks; risks inherent to equity and debt markets and their effects on our share price, and such other risks as may be detailed from time to time in the filings made by the Company pursuant to securities regulations, as well as other risks that may presently be unknown to us or which we consider to be immaterial at the time such forward-looking statements are made. As a result of these risks and uncertainties, the Company cannot guarantee that any forward-looking statement will materialize as expected, and the reader is therefore cautioned not to place undue reliance on any forward-looking statements contained in this news release. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement, are made only as of the date of this news release and the Company does not intend to update any of the forward-looking statements contained in this news release except as expressly required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/98342
